|18.49|| +0.08 / +0.43%|
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric (stomach) cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that are developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA.
|Aron M. Knickerbocker||President, Chief Executive Officer & Director|
|Linda M. Rubinstein||Chief Financial & Accounting Officer|
|Helen Collins||Chief Medical Officer & Senior Vice President|
|Bryan Irving||Chief Scientific Officer & Executive VP|
|Kevin P. Baker||Senior Vice President-Development Sciences|